Bio-Rad Laboratories, Inc. (NYSE:BIO) is set to announce third quarter earning results on Thursday 29th October 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, BIO to report 3Q20 income of $ 1.80 per share.
For the full year, analysts anticipate top line of $ 2314.19 million, while looking forward to income of $ 7.92 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 2,416.00 million ~ $ 2,433.00 million
Click Here For More Historical Outlooks Of Bio-Rad Laboratories, Inc.
Previous Quarter Performance
Bio-Rad Laboratories, Inc. outlined income for the second quarter of $ 1.61 per share, from the revenue of $ 536.88 million. The quarterly earnings increased 8.05 percent while revenues dropped 6.24 percent compared with the same quarter last year.
Street analysts expected Bio-Rad Laboratories, Inc. to report income of $ 1.22 per share on revenue of $ 517.05 million for the second quarter. The bottom line results beat street analysts by $ 0.39 or 31.97 percent, at the same time, top line results outshined analysts by $ 19.83 million or 3.84 percent.
Stock Performance
Shares of Bio-Rad Laboratories, Inc. traded low $ -30.08 or -5.10 percent on Wednesday, reaching $ 559.46 with volume of 180.60 thousand shares. Bio-Rad Laboratories, Inc. has traded high as $ 581.89 and has cracked $ 558.36 on the downward trend
According to the previous trading day, closing price of $ 559.46, representing a 90.56 % increase from the 52 week low of $ 309.38 and a 0.53 % decrease over the 52 week high of $ 592.66.
The company has a market capital of $ 16.54 billion and is part of the Healthcare sector and Diagnostics & Research industry.
Conference Call
Bio-Rad Laboratories, Inc. will be hosting a conference call at 6:00 PM eastern time on 29th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.bio-rad.com
Bio-Rad Laboratories, Inc. develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.
